Why the study?
What variables predict symptomatic pulmonary disease in patients with anaplastic gliomas treated with carmustine?
What variables predict symptomatic pulmonary disease in patients with anaplastic gliomas treated with carmustine?
An equation using clinical and treatment variables can predict carmustine-induced pulmonary toxicity with 80% accuracy in patients with anaplastic gliomas.
Answers are grounded in this paper and cite their sources.
May aid pre-treatment risk stratification for carmustine pulmonary toxicity; leaves open prospective validation before clinical adoption.
Symptomatic pulmonary disease occurred in 20 per cent of 93 patients with anaplastic gliomas being treated with carmustine (BCNU). An analysis of the variables has revealed a relation between the occurrence of pulmonary toxicity on the one hand, and the total cumulative dose of BCNU, the number of cycles over which the BCNU was administered, the history of lung disease, the patient's age, and the platelet-count nadir after the first course of BCNU on the other. An equation has been generated that allows prediction of pulmonary toxicity during the course of therapy with BCNU with 80 per cent accuracy. Pretreatment analysis of individual cases should allow safe use of BCNU and prevention of most of the serious pulmonary complications caused by this drug.
No takes yet. Share an insight, caveat, or question.
Aronin et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: